What is the recommended disease-modifying antirheumatic drug (DMARD) regimen for an adult with inflammatory arthritis who cannot use NSAIDs?

DMARD Regimen for Inflammatory Arthritis

For adults with inflammatory arthritis who cannot use NSAIDs, initiate methotrexate monotherapy at 15 mg weekly, rapidly escalating to 20-25 mg weekly within 4-6 weeks, combined with folic acid supplementation and short-term low-dose glucocorticoids (≤10 mg/day prednisone equivalent) as bridging therapy. 1, 2

Initial DMARD Selection and Dosing

• Methotrexate is the anchor drug and mandatory first-line therapy for rheumatoid arthritis and other inflammatory arthritides, regardless of NSAID availability. 1, 2

• Start oral methotrexate at 7.5-10 mg weekly, then rapidly escalate to 20-25 mg weekly (or 16 mg in Asian populations) within 4-6 weeks to maximize efficacy. 2

• Always prescribe folic acid supplementation with methotrexate to reduce gastrointestinal and hematologic side effects. 2, 3

• Add low-dose glucocorticoids (≤10 mg/day prednisone equivalent) as temporary bridging therapy for up to 6 months while awaiting DMARD effect, then taper as rapidly as clinically feasible. 2

Treatment Monitoring and Escalation Algorithm

• Monitor disease activity every 1-3 months using validated measures; if no improvement by 3 months or target not reached by 6 months, adjust therapy immediately. 2, 4

• If oral methotrexate causes gastrointestinal intolerance or inadequate response at maximum oral dosing, switch to subcutaneous methotrexate (which shows 85% ACR20 response vs. 77% oral). 1, 2

After 3 Months of Optimized Methotrexate:

• If inadequate response and poor prognostic factors present (high RF/anti-CCP, erosive disease, high disease activity): Add a biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) to methotrexate. 2, 4

• Preferred biologic options include TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) combined with methotrexate for optimal efficacy. 2, 5, 4

• Alternative biologics include IL-6 inhibitors (tocilizumab, sarilumab), T-cell costimulation inhibitors (abatacept), or B-cell depleting agents (rituximab). 2, 4

• JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) may be considered, but only after careful assessment of cardiovascular risk, malignancy risk, and thromboembolic risk. 4

If First Biologic/Targeted Synthetic DMARD Fails:

• Switch to any other bDMARD (from another or the same class) or tsDMARD, continuing methotrexate as the backbone therapy. 4

Alternative First-Line DMARDs (When Methotrexate Contraindicated)

• If methotrexate is contraindicated (hepatic/renal disease, MTX-induced lung disease, pregnancy): Use leflunomide or sulfasalazine as alternative first-line csDMARDs. 2

• Hydroxychloroquine has limited efficacy as monotherapy and shows no structural efficacy in preventing joint damage; reserve only for very mild disease or as part of triple therapy (methotrexate + sulfasalazine + hydroxychloroquine). 2

Special Population Considerations

• Serious infection within previous 12 months: Add/switch to csDMARDs over initiating/escalating glucocorticoids. 2

• Nontuberculous mycobacterial lung disease: Add csDMARDs over bDMARDs/tsDMARDs; if biologics needed, use abatacept over TNF inhibitors. 2

• Heart failure (NYHA class III or IV): Use non-TNF inhibitor bDMARDs or tsDMARDs instead of TNF inhibitors due to increased mortality risk. 2

• Previous lymphoproliferative disorder: Rituximab is preferred over other DMARDs. 2

• Hepatitis B core antibody positive: Strongly recommend prophylactic antiviral therapy when initiating rituximab or other b/tsDMARDs. 2

Treat-to-Target Strategy

• Aim for remission or low disease activity as the therapeutic target, adjusting therapy systematically based on validated disease activity measures. 1, 2, 4

• This approach is strongly recommended to minimize inflammation, prevent joint damage, and reduce long-term sequelae including cardiovascular disease and osteoporosis. 1

• Once sustained remission is achieved, DMARDs may be tapered but should not be stopped completely. 4

Critical Pitfalls to Avoid

• Never use hydroxychloroquine as first-line monotherapy when methotrexate is appropriate - this delays effective disease control and allows progressive joint damage. 2

• Never neglect folic acid supplementation with methotrexate, as this leads to unnecessary toxicity and treatment discontinuation. 2

• Never continue ineffective therapy beyond 3-6 months - failure to escalate treatment promptly results in irreversible joint damage. 2, 4

• Never use glucocorticoids as monotherapy for disease modification; they are adjunctive therapy only and must be tapered within 6 months. 2

• Screen for tuberculosis before initiating TNF inhibitors and monitor for infections throughout treatment. 2